GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Collegium Pharmaceutical Inc (NAS:COLL) » Definitions » Cyclically Adjusted PS Ratio

Collegium Pharmaceutical (Collegium Pharmaceutical) Cyclically Adjusted PS Ratio : 3.53 (As of Jun. 01, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Collegium Pharmaceutical Cyclically Adjusted PS Ratio?

As of today (2024-06-01), Collegium Pharmaceutical's current share price is $33.13. Collegium Pharmaceutical's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $9.38. Collegium Pharmaceutical's Cyclically Adjusted PS Ratio for today is 3.53.

The historical rank and industry rank for Collegium Pharmaceutical's Cyclically Adjusted PS Ratio or its related term are showing as below:

COLL' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.34   Med: 3.59   Max: 4.38
Current: 3.46

During the past years, Collegium Pharmaceutical's highest Cyclically Adjusted PS Ratio was 4.38. The lowest was 2.34. And the median was 3.59.

COLL's Cyclically Adjusted PS Ratio is ranked worse than
70.7% of 744 companies
in the Drug Manufacturers industry
Industry Median: 2.085 vs COLL: 3.46

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Collegium Pharmaceutical's adjusted revenue per share data for the three months ended in Mar. 2024 was $3.497. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $9.38 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Collegium Pharmaceutical Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Collegium Pharmaceutical's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Collegium Pharmaceutical Cyclically Adjusted PS Ratio Chart

Collegium Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 3.40

Collegium Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 2.47 3.40 4.14

Competitive Comparison of Collegium Pharmaceutical's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Collegium Pharmaceutical's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Collegium Pharmaceutical's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Collegium Pharmaceutical's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Collegium Pharmaceutical's Cyclically Adjusted PS Ratio falls into.



Collegium Pharmaceutical Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Collegium Pharmaceutical's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=33.13/9.38
=3.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Collegium Pharmaceutical's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Collegium Pharmaceutical's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=3.497/131.7762*131.7762
=3.497

Current CPI (Mar. 2024) = 131.7762.

Collegium Pharmaceutical Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 0.000 101.688 0.000
201609 0.017 101.861 0.022
201612 0.048 101.863 0.062
201703 0.074 102.862 0.095
201706 0.121 103.349 0.154
201709 0.402 104.136 0.509
201712 0.332 104.011 0.421
201803 1.937 105.290 2.424
201806 2.216 106.317 2.747
201809 2.126 106.507 2.630
201812 2.228 105.998 2.770
201903 2.236 107.251 2.747
201906 2.247 108.070 2.740
201909 2.179 108.329 2.651
201912 2.200 108.420 2.674
202003 2.182 108.902 2.640
202006 2.224 108.767 2.694
202009 2.258 109.815 2.710
202012 2.152 109.897 2.580
202103 2.131 111.754 2.513
202106 2.009 114.631 2.309
202109 2.174 115.734 2.475
202112 0.678 117.630 0.760
202203 2.487 121.301 2.702
202206 3.634 125.017 3.830
202209 3.674 125.227 3.866
202212 3.860 125.222 4.062
202303 4.218 127.348 4.365
202306 3.163 128.729 3.238
202309 3.250 129.860 3.298
202312 2.427 129.419 2.471
202403 3.497 131.776 3.497

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Collegium Pharmaceutical  (NAS:COLL) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Collegium Pharmaceutical Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Collegium Pharmaceutical's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Collegium Pharmaceutical (Collegium Pharmaceutical) Business Description

Traded in Other Exchanges
Address
100 Technology Center Drive, Stoughton, MA, USA, 02072
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release & immediate-release formulations of tapentadol.
Executives
Scott Dreyer officer: EVP & Chief Commercial Officer 780 DEDHAM STREET, SUITE 800, CANTON MA 02021
Joseph Ciaffoni director, officer: President and CEO 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
Shirley R. Kuhlmann officer: EVP and General Counsel 780 DEDHAM STREET, SUITE 800, CANTON MA 02021
Michael Thomas Heffernan director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Tupper Colleen officer: EVP & Chief Financial Officer C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
Garen G Bohlin director C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER STREET, WALTHAM MA 02451
Rita J. Balice-gordon director C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
John A. Fallon director C/O INSULET CORPORATION, 9 OAK PARK DRIVE, BEDFORD MA 01730
John Gordon Freund director 125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301
Gwen A Melincoff director C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Gino Santini director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Neil F. Mcfarlane director C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
Thomas B Smith officer: EVP and Chief Medical Officer BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE SUITE 225, RALEIGH NC 27612
Richard Malamut officer: EVP and Chief Medical Officer 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072
Alison B Fleming officer: Vice President, Product Devlp 780 DEDHAM STREET, SUITE 800, CANTON MA 02021

Collegium Pharmaceutical (Collegium Pharmaceutical) Headlines